Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers

Colloids and Surfaces B: Biointerfaces

Volumn 83, Issue 2, 2011, Pages 299-306

  Kuo, Yung Chih ^a   Chung, Jui Fang ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Human serum albumin; Nanostructured lipid carrier; Nevirapine; Solid lipid nanoparticle; Surface charge

Indexed keywords

AMMONIUM BROMIDES; AVERAGE DIAMETER; HUMAN BRAIN; HUMAN SERUM ALBUMINS; LIPID PHASE; MICROVASCULAR ENDOTHELIAL CELLS; NANOCARRIERS; NANOSTRUCTURED LIPID CARRIERS; NEVIRAPINE; PHYSICOCHEMICAL PROPERTY; POSITIVE CHARGES; SOLID LIPID NANOPARTICLE; SOLID LIPID NANOPARTICLES; THERMAL RESISTANCE;

AMMONIUM COMPOUNDS; BODY FLUIDS; BROMINE COMPOUNDS; CHARGED PARTICLES; ENDOTHELIAL CELLS; OLEIC ACID; ZETA POTENTIAL;

NANOPARTICLES;

DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; HUMAN SERUM ALBUMIN; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; NEVIRAPINE; OLEIC ACID; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; HEAT TOLERANCE; HUMAN; HUMAN CELL; MELTING POINT; MICROVASCULAR ENDOTHELIAL CELL; NANOCHEMISTRY; NANOFABRICATION; PARTICLE SIZE; PHASE TRANSITION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURFACE CHARGE; ZETA POTENTIAL;

BRAIN; CHEMISTRY, PHYSICAL; DRUG CARRIERS; ENDOTHELIAL CELLS; HUMANS; LIPIDS; MICROCIRCULATION; NANOSTRUCTURES; NEVIRAPINE; PARTICLE SIZE; QUATERNARY AMMONIUM COMPOUNDS; SERUM ALBUMIN; SURFACE PROPERTIES;

EID: 78651433714     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.11.037     Document Type: Article

References (47)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338:853-860.
2. Lallemant M., Jourdain G., Le Coeur S., Mary J.Y., Ngo-Giang-Huong N., Koetsawang S., Kanshana S., McInstosh K., Thaineua V. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 2004, 351:217-228.
3. Mugavero M.J., Hicks C.B. HIV resistance and the effectiveness of combination antiretroviral treatment. Drug Discov. Today 2004, 1:529-535.
4. Antunes A.M.M., Duarte M.P., Santos P.P., da Costa G.G., Heinze T.M., Beland F.A., Marques M.M. Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine. Chem. Res. Toxicol. 2008, 21:1443-1456.
5. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. 1998, 20:1071-1092.
6. Eldem T., Speiser P., Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm. Res. 1991, 8:47-54.
7. Kuo Y.C., Chen H.H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 2009, 365:206-213.
8. Kuo Y.C., Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 2007, 340:143-152.
9. Muller R.H., Maassen S., Schwarz C., Mehnert W. Solid lipid nanopaticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Controlled Release 1997, 47:261-269.
10. Fundaro A., Cavalli R., Bagoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin pharmacokinetics and tissue distribution after i.v. administration to rats. Pharm. Res. 2000, 42:337-343.
11. Wang J.X., Sun X., Zhang Z.R. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2002, 54:285-290.
12. Bargoni A., Cavalli R., Caputo O., Fundaro A., Gasco M.R., Zara G.P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 1998, 15:745-750.
13. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Controlled Release 1999, 59:299-307.
14. Couvreur P., Dubernet C., Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trend. Eur. J. Pharm. Biopharm. 1995, 41:2-13.
15. Dugaiczyk A., Law S.W., Dennison O.E. Nucleotide sequence and the encoded amino acids of human serum albumin mRNA. Proc. Natl. Acad. Sci. USA 1982, 79:71-75.
16. Chuang V.T., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002, 19:569-577.
17. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications 1995, Elsevier, San Diego.
18. Iglesias J., Abernethy V.E., Wang Z., Lieberthal W., Koh J.S., Levine J.S. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am. J. Physiol. 1999, 277:F711-F722.
19. Wratten M.L., Sereni L., Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren. Fail. 2001, 23:563-571.
20. Kragh-Hansen U., Chung V.T., Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 2002, 25:695-704.
21. Feinstein S.B., Cheirif J., Ten Cate F.J., Silverman P.R., Heidenreich P.A., Dick C., Desir R.M., Armstrong W.F., Quinones M.A., Shah P.M. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J. Am. Coll. Cardiol. 1990, 16:316-324.
22. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 2002, 8:1038-1044.
23. Kuo Y.C., Chen H.H. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J. Drug Target 2010, 18:447-456.
24. Kuo Y.C. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 2005, 290:161-172.
25. Y.C. Kuo, P.I. Lin, Targeting nevirapine delivery across human brain microvesscular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles, Nanomedicine, (2011) in press.
26. Kuo Y.C., Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 2006, 327:160-169.
27. Kuo Y.C., Chung C.Y. Transport of zidovudine- and lamivudine-loaded polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate nanoparticles across the in vitro blood-brain barrier: characteristics of the drug-delivery system. J. Chin. Inst. Chem. Eng. 2005, 36:627-638.
28. Hac-Wydro K., Wydro P. The influence of fatty acids on model cholesterol/phospholipid membranes. Chem. Phys. Lipids 2007, 150:66-81.
29. Aquilano D., Cavalli R., Gasco M.R. Solid lipospheres obtained from hot microemulsions in the presence of different concentrations of cosurfactant: the crystallization of stearic acid polymorphs. Thermochim. Acta 1993, 230:29-37.
30. Boltri L., Canal T., Esposito P. Relevant factors affecting the formation and growth of lipid nanospheres suspensions. Eur. J. Pharm. Biopharm. 1995, 41:70-75.
31. Kuo Y.C., Shih K.H., Yang J.T. Capillary electrophoresis of bone marrow stromal cells with the uptake of heparin-functionalized poly(lactide-co-glycolide) nanoparticles during differentiation towards neurons. Electrophoresis 2010, 31:315-323.
32. Kuo Y.C., Lin T.W. Electrophoretic mobility, zeta potential, and fixed charge density of bovine knee chondrocytes, methylmethacrylate-sulfopropylmethacrylate, polybutylcyanoacrylate, and solid lipid nanoparticles. J. Phys. Chem. B 2006, 110:2202-2208.
33. Kuo Y.C. Adsorption of a biocolloid onto a rigid charged surface: characteristics of functional group, membrane and electrolytic solution. J. Chin. Inst. Chem. Eng. 2003, 34:117-186.
34. Ohshima H. Electrophoresis of soft particles: analytic approximations. Electrophoresis 2006, 27:526-533.
35. Kuo Y.C., Wang C.C. Electrophoresis of human brain microvascular endothelial cells with uptake of cationic solid lipid nanoparticles: effect of surfactant composition. Colloids Surf. B 2010, 76:286-291.
36. Makino K., Yamamoto N., Higuchi K., Harada N., Ohshima H., Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf. B 2003, 27:33-39.
37. Depalo N., Mallardi A., Comparelli R., Striccoli M., Agostiano A. Luminescent nanocrystals in phospholipid micelles for bioconjugation: an optical and structural investigation. J. Colloid Interface Sci. 2008, 325:558-566.
38. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
39. Sharma P., Ganta S., Denny W.A., Garg A. Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: chlorambucil. Int. J. Pharm. 2009, 367:187-194.
40. Kuo Y.C., Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 2008, 351:271-281.
41. Scholer N., Hahn H., Muller R.H., Liesenfeid O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 2002, 231:167-176.
42. Kuo Y.C., Lin S.C. Effect of glutamate on the electrical properties of cationic solid lipid nanoparticles containing stearylamine and dioctadecyldimethyl ammonium bromide. J. Phys. Chem. B 2008, 112:4454-4460.
43. Kuo Y.C., Chen I.C. Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain-microvascular endothelial cells. J. Phys. Chem. B 2007, 111:11228-11236.
44. Catelas I., Petit A., Marchand R., Zukor D.J., Yahia L.H., Huk O.L. Cytotoxicity and macrophage cytokine release induced by ceramic and polyethylene particles in vitro. J. Bone Joint Surg. 1999, 81-B:516-521.
45. Goodman C.M., McCusker C.D., Yilmaz T., Rotello V.M. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjugate Chem. 2004, 15:897-900.
46. Vauthier C., Dubernet C., Fattal E., Patrick C. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 2003, 55:519-548.
47. Lherm C., Muller R., Puisieux F., Couvreur P. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int. J. Pharm. 1992, 84:13-22.